Karin Jirström

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8261944/publications.pdf

Version: 2024-02-01

222 papers 12,878 citations

56 h-index 100 g-index

226 all docs

226 docs citations

times ranked

226

22048 citing authors

#	Article	IF	CITATIONS
1	Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discovery, 2011, 1, 54-67.	9.4	1,486
2	Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature, 2020, 577, 561-565.	27.8	1,209
3	Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer. Clinical Cancer Research, 2011, 17, 6083-6096.	7.0	330
4	Isolation and Characterization of Progenitor-Like Cells from Human Renal Proximal Tubules. American Journal of Pathology, 2011, 178, 828-837.	3.8	231
5	Prognostic Significance of Stromal Platelet-Derived Growth Factor β-Receptor Expression in Human Breast Cancer. American Journal of Pathology, 2009, 175, 334-341.	3.8	215
6	SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal Carcinomas. American Journal of Surgical Pathology, 2011, 35, 937-948.	3.7	209
7	Prognostic impact of tumourâ€infiltrating B cells and plasma cells in colorectal cancer. International Journal of Cancer, 2016, 139, 1129-1139.	5.1	192
8	Nuclear expression of the non–B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood, 2008, 111, 800-805.	1.4	185
9	Effect of Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma in Situ: 20 Years Follow-Up in the Randomized SweDCIS Trial. Journal of Clinical Oncology, 2014, 32, 3613-3618.	1.6	184
10	Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Research and Treatment, 2013, 138, 499-508.	2.5	183
11	Association Between Pak1 Expression and Subcellular Localization and Tamoxifen Resistance in Breast Cancer Patients. Journal of the National Cancer Institute, 2006, 98, 671-680.	6.3	177
12	Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. Journal of Clinical Investigation, 2011, 121, 784-799.	8.2	177
13	Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget, 2015, 6, 12297-12309.	1.8	148
14	STC1 Expression By Cancer-Associated Fibroblasts Drives Metastasis of Colorectal Cancer. Cancer Research, 2013, 73, 1287-1297.	0.9	144
15	Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Scientific Reports, 2016, 6, 18517.	3.3	143
16	Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers. Nature Communications, 2016, 7, 13050.	12.8	135
17	Hypoxia-Inducible Factor-2α Correlates to Distant Recurrence and Poor Outcome in Invasive Breast Cancer. Cancer Research, 2008, 68, 9212-9220.	0.9	130
18	Increased claudinâ€4 expression is associated with poor prognosis and high tumour grade in breast cancer. International Journal of Cancer, 2009, 124, 2088-2097.	5.1	128

#	Article	IF	Citations
19	CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance. Clinical Cancer Research, 2006, 12, 6421-6431.	7.0	123
20	High Progesterone Receptor Expression Correlates to the Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer Patients. Clinical Cancer Research, 2006, 12, 4614-4618.	7.0	121
21	Expression of the cytoskeleton linker protein ezrin in human cancers. Clinical and Experimental Metastasis, 2007, 24, 69-78.	3.3	118
22	Adverse Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer with Cyclin D1 Gene Amplification. Cancer Research, 2005, 65, 8009-8016.	0.9	117
23	JAMâ€A expression positively correlates with poor prognosis in breast cancer patients. International Journal of Cancer, 2009, 125, 1343-1351.	5.1	115
24	ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene, 2005, 24, 4370-4379.	5.9	106
25	Classification of Breast Cancer Using Genetic Algorithms and Tissue Microarrays. Clinical Cancer Research, 2006, 12, 6459-6468.	7.0	100
26	Wnt5a Induces a Tolerogenic Phenotype of Macrophages in Sepsis and Breast Cancer Patients. Journal of Immunology, 2012, 188, 5448-5458.	0.8	100
27	Heterogeneity of Colorectal Cancer Risk Factors by Anatomical Subsite in 10 European Countries: AÂMultinational Cohort Study. Clinical Gastroenterology and Hepatology, 2019, 17, 1323-1331.e6.	4.4	99
28	CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. International Journal of Cancer, 2007, 120, 1434-1443.	5.1	98
29	Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma. Clinical Cancer Research, 2012, 18, 4026-4036.	7.0	96
30	A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk. Clinical Cancer Research, 2018, 24, 5895-5901.	7.0	88
31	Forkhead Box F1 Regulates Tumor-Promoting Properties of Cancer-Associated Fibroblasts in Lung Cancer. Cancer Research, 2010, 70, 2644-2654.	0.9	84
32	Altered Cytoplasmic-to-Nuclear Ratio of Survivin Is a Prognostic Indicator in Breast Cancer. Clinical Cancer Research, 2008, 14, 2681-2689.	7.0	83
33	Aberrantly activated claudin 6 and 18.2 as potential therapy targets in nonâ€smallâ€cell lung cancer. International Journal of Cancer, 2014, 135, 2206-2214.	5.1	82
34	ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer. BMC Cancer, 2016, 16, 904.	2.6	82
35	A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort. Clinical Cancer Research, 2016, 22, 4664-4675.	7.0	80
36	Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer. Cancer Research, 2017, 77, 3834-3845.	0.9	79

#	Article	IF	Citations
37	High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers. Breast Cancer Research and Treatment, 2017, 164, 667-678.	2.5	79
38	Polymorphisms in fatty acid metabolism-related genes are associated with colorectal cancer risk. Carcinogenesis, 2010, 31, 466-472.	2.8	77
39	Downregulation of miR-92a Is Associated with Aggressive Breast Cancer Features and Increased Tumour Macrophage Infiltration. PLoS ONE, 2012, 7, e36051.	2.5	76
40	Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer. Journal of Ovarian Research, 2016, 9, 21.	3.0	76
41	miR-187 Is an Independent Prognostic Factor in Breast Cancer and Confers Increased Invasive Potential <i>In Vitro</i> . Clinical Cancer Research, 2012, 18, 6702-6713.	7.0	75
42	Tumor characteristics and prognosis in women with pregnancyâ€associated breast cancer. International Journal of Cancer, 2018, 142, 1343-1354.	5.1	75
43	The Prognostic Significance of Tryptophanyl-tRNA Synthetase in Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2949-2956.	2.5	71
44	Hypoxia inducible factor‶α is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. International Journal of Cancer, 2006, 118, 2609-2616.	5.1	70
45	The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs. Journal of Thoracic Oncology, 2016, 11, 862-872.	1.1	70
46	Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. Modern Pathology, 2009, 22, 1564-1574.	5.5	69
47	Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Research and Treatment, 2010, 120, 491-498.	2.5	69
48	Anthropometric measures and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2010, 126, 2404-2415.	5.1	68
49	Pre-diagnostic concordance with the WCRF/AICR guidelines and survival in European colorectal cancer patients: a cohort study. BMC Medicine, 2015, 13, 107.	5.5	66
50	Immune effector monocyte–neutrophil cooperation induced by the primary tumor prevents metastatic progression of breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 21704-21714.	7.1	66
51	The clinical impact of tumourâ€infiltrating lymphocytes in colorectal cancer differs by anatomical subsite: A cohort study. International Journal of Cancer, 2017, 141, 1654-1666.	5.1	65
52	Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort. Clinical Cancer Research, 2015, 21, 3640-3650.	7.0	64
53	Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma. Journal of Gastrointestinal Oncology, 2016, 7, 848-859.	1.4	64
54	CD99 is a novel prognostic stromal marker in nonâ€small cell lung cancer. International Journal of Cancer, 2012, 131, 2264-2273.	5.1	63

#	Article	IF	Citations
55	Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma. BMC Medicine, 2017, 15, 101.	5.5	62
56	<scp>CDK</scp> â€mediated activation of the <scp>SCF^{FBXO}</scp> ²⁸ ubiquitin ligase promotes <scp>MYC</scp> â€driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Molecular Medicine, 2013, 5, 1067-1086.	6.9	61
57	Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer. Oncotarget, 2015, 6, 22028-22037.	1.8	61
58	Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis. Oncolmmunology, 2018, 7, e1465165.	4.6	59
59	Down-Regulation of the Oncogene Cyclin D1 Increases Migratory Capacity in Breast Cancer and Is Linked to Unfavorable Prognostic Features. American Journal of Pathology, 2010, 177, 2886-2897.	3.8	58
60	LGR5 in breast cancer and ductal carcinoma in situ: a diagnostic and prognostic biomarker and a therapeutic target. BMC Cancer, 2020, 20, 542.	2.6	58
61	Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer. British Journal of Cancer, 2016, 114, 1117-1124.	6.4	57
62	Coffee and tea consumption and the risk of ovarian cancer: a prospective cohort study and updated meta-analysis. American Journal of Clinical Nutrition, 2012, 95, 1172-1181.	4.7	56
63	Immunohistochemistry in the Differential Diagnostics of Primary Lung Cancer. American Journal of Clinical Pathology, 2013, 140, 37-46.	0.7	56
64	HMG oA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors. International Journal of Cancer, 2008, 123, 1146-1153.	5.1	55
65	RBM3-Regulated Genes Promote DNA Integrity and Affect Clinical Outcome in Epithelial Ovarian Cancer. Translational Oncology, 2011, 4, 212-IN1.	3.7	54
66	BRCA1â€like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential. Molecular Oncology, 2015, 9, 1528-1538.	4.6	54
67	Prognostic Impact of Tumor Cell Programmed Death Ligand 1 Expression and Immune Cell Infiltration in NSCLC. Journal of Thoracic Oncology, 2019, 14, 628-640.	1.1	54
68	Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial. Journal of Translational Medicine, 2015, 13, 133.	4.4	53
69	The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma. Oncotarget, 2017, 8, 72108-72126.	1.8	53
70	Breast tumours following combined hormone replacement therapy express favourable prognostic factors. International Journal of Cancer, 2007, 120, 2202-2207.	5.1	51
71	Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: An analysis of 215 cases from the Malmö Diet and Cancer Study. Journal of Translational Medicine, 2011, 9, 114.	4.4	51
72	Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma. Journal of Translational Medicine, 2014, 12, 289.	4.4	49

#	Article	IF	Citations
73	Contribution of Antibody-based Protein Profiling to the Human Chromosome-centric Proteome Project (C-HPP). Journal of Proteome Research, 2013, 12, 2439-2448.	3.7	48
74	Stage at diagnosis and mortality in women with pregnancy-associated breast cancer (PABC). Breast Cancer Research and Treatment, 2013, 139, 183-192.	2.5	47
75	Cysteinyl leukotriene receptor expression pattern affects migration of breast cancer cells and survival of breast cancer patients. International Journal of Cancer, 2011, 129, 9-22.	5.1	46
76	Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation. Journal of Investigative Dermatology, 2015, 135, 1820-1828.	0.7	46
77	Subtypes of fruit and vegetables, variety in consumption and risk of colon and rectal cancer in the <scp>E</scp> uropean <scp>P</scp> rospective <scp>I</scp> nvestigation into <scp>C</scp> ancer and <scp>N</scp> utrition. International Journal of Cancer, 2015, 137, 2705-2714.	5.1	45
78	Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer. Oncotarget, 2017, 8, 34796-34810.	1.8	45
79	The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. BMC Cancer, 2015, 15, 468.	2.6	44
80	Prognostic and predictive significance of podocalyxin-like protein expression in pancreatic and periampullary adenocarcinoma. BMC Clinical Pathology, 2015, 15, 10.	1.8	43
81	Pre-diagnostic anthropometry and survival after colorectal cancer diagnosis in Western European populations. International Journal of Cancer, 2014, 135, 1949-1960.	5.1	42
82	WNT5A-mediated Â-catenin-independent signalling is a novel regulator of cancer cell metabolism. Carcinogenesis, 2014, 35, 784-794.	2.8	42
83	A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen. Cell Cycle, 2011, 10, 956-962.	2.6	41
84	Low PIP4K2B Expression in Human Breast Tumors Correlates with Reduced Patient Survival: A Role for PIP4K2B in the Regulation of E-Cadherin Expression. Cancer Research, 2013, 73, 6913-6925.	0.9	41
85	Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer. Breast Cancer Research, 2015, 17, 130.	5.0	41
86	Cigarette smoking and risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study. International Journal of Cancer, 2012, 130, 2204-2210.	5.1	40
87	Coffee, tea and melanoma risk: findings from the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2017, 140, 2246-2255.	5.1	39
88	Immunohistochemical profiles in primary lung cancers and epithelial pulmonary metastases. Human Pathology, 2019, 84, 221-230.	2.0	39
89	Quantitative, qualitative and spatial analysis of lymphocyte infiltration in periampullary and pancreatic adenocarcinoma. International Journal of Cancer, 2020, 146, 3461-3473.	5.1	39
90	Diagnostic Value of Insulinoma-Associated Protein 1 (INSM1) and Comparison With Established Neuroendocrine Markers in Pulmonary Cancers. Archives of Pathology and Laboratory Medicine, 2020, 144, 1075-1085.	2.5	38

#	Article	IF	Citations
91	Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. Journal of Ovarian Research, 2010, 3, 14.	3.0	37
92	Anthropometric factors in relation to different tumor biological subgroups of postmenopausal breast cancer. International Journal of Cancer, 2009, 124, 402-411.	5.1	36
93	Expression of PD-L1 and PD-1 in Chemoradiotherapy-Na \tilde{A}^- ve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival. Frontiers in Oncology, 2019, 9, 136.	2.8	36
94	Plasma Folate Concentrations Are Positively Associated with Risk of Estrogen Receptor \hat{l}^2 Negative Breast Cancer in a Swedish Nested Case Control Study. Journal of Nutrition, 2010, 140, 1661-1668.	2.9	35
95	The î"Np63 Proteins Are Key Allies of BRCA1 in the Prevention of Basal-Like Breast Cancer. Cancer Research, 2011, 71, 1933-1944.	0.9	35
96	Coffee and tea consumption, genotype-based <i>CYP1A2</i> and <i>NAT2</i> ectivity and colorectal cancer risk-Results from the EPIC cohort study. International Journal of Cancer, 2014, 135, 401-412.	5.1	35
97	S100A9 expressed in ERâ^'PgRâ^' breast cancers induces inflammatory cytokines and is associated with an impaired overall survival. British Journal of Cancer, 2015, 113, 1234-1243.	6.4	35
98	Prediagnostic Intake of Dairy Products and Dietary Calcium and Colorectal Cancer Survivalâ€"Results from the EPIC Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1813-1823.	2.5	34
99	Clinical impact of T cells, B cells and the PD-1/PD-L1 pathway in muscle invasive bladder cancer: a comparative study of transurethral resection and cystectomy specimens. Oncolmmunology, 2019, 8, e1644108.	4.6	34
100	Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer. Oncotarget, 2016, 7, 76920-76933.	1.8	34
101	G Protein–Coupled Estrogen Receptor Is Apoptotic and Correlates with Increased Distant Disease-Free Survival of Estrogen Receptor–Positive Breast Cancer Patients. Clinical Cancer Research, 2013, 19, 1681-1692.	7.0	33
102	Weight change later in life and colon and rectal cancer risk in participants in the EPIC-PANACEA study. American Journal of Clinical Nutrition, 2014, 99, 139-147.	4.7	33
103	Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer. BMC Cancer, 2016, 16, 603.	2.6	33
104	The clinical importance of tumour-infiltrating macrophages and dendritic cells in periampullary adenocarcinoma differs by morphological subtype. Journal of Translational Medicine, 2017, 15, 152.	4.4	33
105	The emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPL. Biochemical Society Transactions, 2011, 39, 663-668.	3.4	32
106	Associations of Anthropometric Factors with KRAS and BRAF Mutation Status of Primary Colorectal Cancer in Men and Women: A Cohort Study. PLoS ONE, 2014, 9, e98964.	2.5	32
107	Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma. PLoS ONE, 2016, 11, e0153533.	2.5	32
108	The Prognostic Impact of NK/NKT Cell Density in Periampullary Adenocarcinoma Differs by Morphological Type and Adjuvant Treatment. PLoS ONE, 2016, 11, e0156497.	2.5	32

#	Article	IF	Citations
109	15-Prostaglandin Dehydrogenase Expression Alone or in Combination with ACSM1 Defines a Subgroup of the Apocrine Molecular Subtype of Breast Carcinoma. Molecular and Cellular Proteomics, 2008, 7, 1795-1809.	3.8	31
110	Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis. Modern Pathology, 2011, 24, 708-719.	5.5	31
111	Sushi domainâ€containing protein 4 (SUSD4) inhibits complement by disrupting the formation of the classical C3 convertase. FASEB Journal, 2013, 27, 2355-2366.	0.5	31
112	High expression of RNA-binding motif protein 3 in esophageal and gastric adenocarcinoma correlates with intestinal metaplasia-associated tumours and independently predicts a reduced risk of recurrence and death. Biomarker Research, 2014, 2, 11.	6.8	31
113	Pre-diagnostic meat and fibre intakes in relation to colorectal cancer survival in the European Prospective Investigation into Cancer and Nutrition. British Journal of Nutrition, 2016, 116, 316-325.	2.3	30
114	Hormonal factors and pancreatic cancer risk in women: The <code><scp>M</scp>almö <scp>D</scp>iet and <code><scp>C</scp>ancer <scp>S</scp>tudy. International Journal of Cancer, 2018, 143, 52-62.</code></code>	5.1	30
115	Immunohistochemical detection of tyrosine phosphatase SHPâ€₁ predicts outcome after radical prostatectomy for localized prostate cancer. International Journal of Cancer, 2010, 126, 2296-2307.	5.1	28
116	Use of a standardized diagnostic approach improves the prognostic information of histopathologic factors in pancreatic and periampullary adenocarcinoma. Diagnostic Pathology, 2014, 9, 80.	2.0	28
117	Prognostic impact of COX-2 in non-small cell lung cancer: A comprehensive compartment-specific evaluation of tumor and stromal cell expression. Cancer Letters, 2015, 356, 837-845.	7.2	28
118	p27 ^{Kip1} is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients. International Journal of Cancer, 2010, 127, 2851-2858.	5.1	27
119	LRIG1 is a prognostic biomarker in non-small cell lung cancer. Acta Oncol $ ilde{A}^3$ gica, 2015, 54, 1113-1119.	1.8	27
120	Comparison of Three Different TTF-1 Clones in Resected Primary Lung Cancer and Epithelial Pulmonary Metastases. American Journal of Clinical Pathology, 2018, 150, 533-544.	0.7	27
121	High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. PLoS ONE, 2017, 12, e0182512.	2.5	27
122	SATB1 is an independent prognostic factor in radically resected upper gastrointestinal tract adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 649-659.	2.8	26
123	Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients. BMC Clinical Pathology, 2015, 15, 8.	1.8	26
124	Discovery of KIRREL as a biomarker for prognostic stratification of patients with thin melanoma. Biomarker Research, 2019, 7, 1.	6.8	26
125	Cyclin E Overexpression Obstructs Infiltrative Behavior in Breast Cancer: A Novel Role Reflected in the Growth Pattern of Medullary Breast Cancers. Cancer Research, 2005, 65, 9727-9734.	0.9	25
126	Receptor Tyrosine Kinase Signaling Favors a Protumorigenic State in Breast Cancer Cells by Inhibiting the Adaptive Immune Response. Cancer Research, 2010, 70, 7776-7787.	0.9	25

#	Article	IF	CITATIONS
127	Tumors with Nonfunctional Retinoblastoma Protein Are Killed by Reduced \hat{I}^3 -Tubulin Levels. Journal of Biological Chemistry, 2012, 287, 17241-17247.	3.4	25
128	Local expression of complement factor I in breast cancer cells correlates with poor survival and recurrence. Cancer Immunology, Immunotherapy, 2015, 64, 467-478.	4.2	25
129	Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinoma. BMC Clinical Pathology, 2016, 16, 13.	1.8	25
130	Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma. Biomarker Research, 2016, 4, 10.	6.8	25
131	The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types. EBioMedicine, 2021, 65, 103269.	6.1	25
132	Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma. PLoS ONE, 2016, 11, e0148101.	2.5	25
133	Association of the oestrogen receptor beta with hormone status and prognosis in a cohort of female patients with colorectal cancer. European Journal of Cancer, 2017, 83, 279-289.	2.8	24
134	Ovarian cancer early detection by circulating <scp>CA</scp> 125 in the context of antiâ€ <scp>CA</scp> 125 autoantibody levels: Results from the <scp>EPIC</scp> cohort. International Journal of Cancer, 2018, 142, 1355-1360.	5.1	24
135	Cyclin A Is a Proliferative Marker with Good Prognostic Value in Node-Negative Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2501-2506.	2.5	23
136	Stromal Expression of \hat{I}^2 -Arrestin-1 Predicts Clinical Outcome and Tamoxifen Response in Breast Cancer. Journal of Molecular Diagnostics, 2011, 13, 340-351.	2.8	23
137	Reduced Expression of the Polymeric Immunoglobulin Receptor in Pancreatic and Periampullary Adenocarcinoma Signifies Tumour Progression and Poor Prognosis. PLoS ONE, 2014, 9, e112728.	2.5	23
138	HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome. Diagnostic Pathology, 2014, 9, 78.	2.0	23
139	Fibre intake and incident colorectal cancer depending on fibre source, sex, tumour location and Tumour, Node, Metastasis stage. British Journal of Nutrition, 2015, 114, 959-969.	2.3	23
140	Analysis of the Human Prostate-Specific Proteome Defined by Transcriptomics and Antibody-Based Profiling Identifies TMEM79 and ACOXL as Two Putative, Diagnostic Markers in Prostate Cancer. PLoS ONE, 2015, 10, e0133449.	2.5	23
141	High Estrogen Receptor β Expression Is Prognostic among Adjuvant Chemotherapy–Treated Patients—Results from a Population-Based Breast Cancer Cohort. Clinical Cancer Research, 2017, 23, 766-777.	7.0	23
142	Erythropoietin Receptor Expression and Correlation to Tamoxifen Response and Prognosis in Breast Cancer. Clinical Cancer Research, 2009, 15, 5552-5559.	7.0	22
143	Infiltration of γâ¢Î´T cells, IL-17+ T cells and FoxP3+ T cells in human breast cancer. Cancer Biomarkers, 2018, 20, 395-409.	1.7	22
144	Expression and prognostic significance of the polymeric immunoglobulin receptor in epithelial ovarian cancer. Journal of Ovarian Research, 2014, 7, 26.	3.0	21

#	Article	IF	CITATIONS
145	Pancreatic cancer risk in relation to sex, lifestyle factors, and pre-diagnostic anthropometry in the Malmö Diet and Cancer Study. Biology of Sex Differences, 2016, 7, 66.	4.1	21
146	Low RBM3 Protein Expression Correlates with Clinical Stage, Prognostic Classification and Increased Risk of Treatment Failure in Testicular Non-Seminomatous Germ Cell Cancer. PLoS ONE, 2015, 10, e0121300.	2.5	21
147	Investigation of molecular alterations of <i><scp>AKT</scp>â€3</i> in tripleâ€negative breast cancer. Histopathology, 2014, 64, 660-670.	2.9	20
148	Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts. BMC Urology, 2014, 14, 36.	1.4	20
149	Tumor-Associated CD68+, CD163+, and MARCO+ Macrophages as Prognostic Biomarkers in Patients With Treatment-Naà ve Gastroesophageal Adenocarcinoma. Frontiers in Oncology, 2020, 10, 534761.	2.8	20
150	Complement inhibitor factor H expressed by breast cancer cells differentiates CD14 ⁺ human monocytes into immunosuppressive macrophages. Oncolmmunology, 2020, 9, 1731135.	4.6	20
151	Multiple Miscarriages Are Associated with the Risk of Ovarian Cancer: Results from the European Prospective Investigation into Cancer and Nutrition. PLoS ONE, 2012, 7, e37141.	2.5	19
152	Intra-tumour IgA1 is common in cancer and is correlated with poor prognosis in bladder cancer Heliyon, 2016, 2, e00143.	3.2	19
153	The prognostic impact of COXâ€⊋ expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size. International Journal of Cancer, 2017, 140, 163-175.	5.1	19
154	Tumorâ€associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation. International Journal of Cancer, 2018, 143, 515-526.	5.1	18
155	Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma. Journal of Translational Medicine, 2018, 16, 66.	4.4	18
156	BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer. Clinical Cancer Research, 2019, 25, 7139-7150.	7.0	18
157	A Functional Genomic Screen Identifies the Deubiquitinase USP11 as a Novel Transcriptional Regulator of ERÎ \pm in Breast Cancer. Cancer Research, 2020, 80, 5076-5088.	0.9	18
158	Topographical Distribution and Spatial Interactions of Innate and Semi-Innate Immune Cells in Pancreatic and Other Periampullary Adenocarcinoma. Frontiers in Immunology, 2020, 11, 558169.	4.8	18
159	Histological specificity of alterations and expression of <i>KIT</i> and <i>KITLG</i> in nonâ€small cell lung carcinoma. Genes Chromosomes and Cancer, 2013, 52, 1088-1096.	2.8	17
160	Discordant human epidermal growth factor receptor 2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis. Histopathology, 2016, 68, 230-240.	2.9	17
161	Reaching the limits of prognostication in non-small cell lung cancer: an optimized biomarker panel fails to outperform clinical parameters. Modern Pathology, 2017, 30, 964-977.	5. 5	17
162	Genetic variation in the ADIPOQ gene, adiponectin concentrations and risk of colorectal cancer: a Mendelian Randomization analysis using data from three large cohort studies. European Journal of Epidemiology, 2017, 32, 419-430.	5.7	17

#	Article	IF	CITATIONS
163	Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1. Molecular Cancer Research, 2020, 18, 644-656.	3.4	17
164	Protein Expression Profiling of Formalin-Fixed Paraffin-Embedded Tissue Using Recombinant Antibody Microarrays. Journal of Proteome Research, 2013, 12, 5943-5953.	3.7	16
165	Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study. Biomarker Research, 2017, 5, 10.	6.8	16
166	Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer. Acta Oncol \tilde{A}^3 gica, 2016, 55, 286-296.	1.8	14
167	CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients. Breast Cancer Research, 2020, 22, 123.	5.0	14
168	T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival. Oncolmmunology, 2021, 10, 1921443.	4.6	14
169	Human G-MDSCs are neutrophils at distinct maturation stages promoting tumor growth in breast cancer. Life Science Alliance, 2020, 3, e202000893.	2.8	14
170	Low expression of SHP-2 is associated with less favorable prostate cancer outcomes. Tumor Biology, 2013, 34, 637-642.	1.8	13
171	A systematic analysis of commonly used antibodies in cancer diagnostics. Histopathology, 2014, 64, 293-305.	2.9	13
172	Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: Implications for prognosis in different treatment groups. Oncotarget, 2017, 8, 9093-9107.	1.8	13
173	Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomarker for improved patient stratification. Oncotarget, 2018, 9, 6188-6200.	1.8	13
174	FKBPL: a marker of good prognosis in breast cancer. Oncotarget, 2015, 6, 12209-12223.	1.8	13
175	CRIM1 is localized to the podocyte filtration slit diaphragm of the adult human kidney. Nephrology Dialysis Transplantation, 2009, 24, 2038-2044.	0.7	12
176	The Target for Statins, HMG-CoA Reductase, Is Expressed in Ductal Carcinoma-In Situ and May Predict Patient Response to Radiotherapy. Annals of Surgical Oncology, 2014, 21, 2911-2919.	1.5	12
177	Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph nodeâ€negative breast cancer patients. FEBS Journal, 2015, 282, 3455-3473.	4.7	12
178	Early diagnostic value of Bcl-3 localization in colorectal cancer. BMC Cancer, 2015, 15, 341.	2.6	12
179	Significant association and synergistic adverse prognostic effect of podocalyxin-like protein and epidermal growth factor receptor expression in colorectal cancer. Journal of Translational Medicine, 2016, 14, 128.	4.4	12
180	Re-evaluation of HER2 status in 606 breast cancersâ€"gene protein assay on tissue microarrays versus routine pathological assessment. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 317-320.	2.8	12

#	Article	IF	CITATIONS
181	Cyclin I is expressed in human breast cancer and closely associated with VEGF and KDR expression. Breast Cancer Research and Treatment, 2005, 89, 313-316.	2.5	11
182	Anthropometric factors and ovarian cancer risk in the Malm $\tilde{A}\P$ Diet and Cancer Study. Cancer Epidemiology, 2011, 35, 432-437.	1.9	11
183	Mucin staining is of limited value in addition to basic immunohistochemical analyses in the diagnostics of non-small cell lung cancer. Scientific Reports, 2019, 9, 1319.	3.3	11
184	Molecular Evolution of Specific Human Antibody against MUC1 Mucin Results in Improved Recognition of the Antigen on Tumor Cells. Tumor Biology, 2009, 30, 221-231.	1.8	10
185	Incident urothelial cancer in the Malm \tilde{A}^{\P} Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker. Diagnostic Pathology, 2014, 9, 189.	2.0	10
186	The human complement inhibitor Sushi Domain-Containing Protein 4 (SUSD4) expression in tumor cells and infiltrating T cells is associated with better prognosis of breast cancer patients. BMC Cancer, 2015, 15, 737.	2.6	10
187	Comprehensive analysis of RNA binding motif protein 3 (RBM3) in nonâ€small cell lung cancer. Cancer Medicine, 2020, 9, 5609-5619.	2.8	10
188	Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment. Journal of Clinical Pathology, 2018, 71, 451-462.	2.0	9
189	Chemotherapy, host response and molecular dynamics in periampullary cancer: the CHAMP study. BMC Cancer, 2020, 20, 308.	2.6	9
190	Primary Melanoma Tumors from CDKN2A Mutation Carriers Do Not Belong to a Distinct Molecular Subclass. Journal of Investigative Dermatology, 2014, 134, 3000-3003.	0.7	8
191	Multiâ€parametric profiling of renal cell, colorectal, and ovarian cancer identifies tumourâ€typeâ€specific stroma phenotypes and a novel vascular biomarker. Journal of Pathology: Clinical Research, 2017, 3, 214-224.	3.0	8
192	Interactions Between ABCB1 Genotype and Preoperative Statin Use Impact Clinical Outcomes Among Breast Cancer Patients. Frontiers in Oncology, 2018, 8, 428.	2.8	8
193	Prognostic impact of tumor-specific insulin-like growth factor binding protein 7 (IGFBP7) levels in breast cancer: a prospective cohort study. Carcinogenesis, 2021, 42, 1314-1325.	2.8	8
194	The \hat{I}^3 -tubulin meshwork assists in the recruitment of PCNA to chromatin in mammalian cells. Communications Biology, 2021, 4, 767.	4.4	8
195	High Infiltration of CD68 ⁺ /CD163 ^{â^'} Macrophages Is an Adverse Prognostic Factor after Neoadjuvant Chemotherapy in Esophageal and Gastric Adenocarcinoma. Journal of Innate Immunity, 2022, 14, 615-628.	3.8	8
196	Serum concentrations of human chorionic gonadotropin beta and its association with survival in patients with colorectal cancer. Cancer Biomarkers, 2012, 11, 173-181.	1.7	7
197	Detecting EGFR alterations in clinical specimens—pitfalls and necessities. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 755-764.	2.8	7
198	Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma. Journal of Translational Medicine, 2018, 16, 290.	4.4	7

#	Article	IF	Citations
199	Coffee Is Associated With Lower Breast Tumor Insulin-Like Growth Factor Receptor 1 Levels in Normal-Weight Patients and Improved Prognosis Following Tamoxifen or Radiotherapy Treatment. Frontiers in Endocrinology, 2018, 9, 306.	3.5	7
200	Inflammatory macrophage derived TNF \hat{l}_{\pm} downregulates estrogen receptor \hat{l}_{\pm} via FOXO3a inactivation in human breast cancer cells. Experimental Cell Research, 2020, 390, 111932.	2.6	7
201	Human Epidermal Growth Factor Receptor-3 Expression Is Regulated at Transcriptional Level in Breast Cancer Settings by Junctional Adhesion Molecule-A via a Pathway Involving Beta-Catenin and FOXA1. Cancers, 2021, 13, 871.	3.7	7
202	Reproductive Factors, Exogenous Hormone Use, and Risk of B-Cell Non-Hodgkin Lymphoma in a Cohort of Women From the European Prospective Investigation Into Cancer and Nutrition. American Journal of Epidemiology, 2019, 188, 274-281.	3.4	6
203	Ovarian cancer subtypes and survival in relation to three comprehensive imaging parameters. Journal of Ovarian Research, 2020, 13, 26.	3.0	6
204	Pre- and Postoperative Circulating IGF-I, IGFBP-3, and IGFBP-7 Levels in Relation to Endocrine Treatment and Breast Cancer Recurrence: A Nested Case-Control Study. Frontiers in Oncology, 2021, 11, 626058.	2.8	6
205	Body Mass Index Influences the Prognostic Impact of Combined Nuclear Insulin Receptor and Estrogen Receptor Expression in Primary Breast Cancer. Frontiers in Endocrinology, 2017, 8, 332.	3.5	5
206	Pre-diagnostic anthropometry, sex, and risk of colorectal cancer according to tumor immune cell composition. Oncolmmunology, 2019, 8, e1664275.	4.6	5
207	Metabolic factors and the risk of small intestine cancers: Pooled study of 800 000 individuals in the metabolic syndrome and cancer project. International Journal of Cancer, 2021, 149, 66-74.	5.1	5
208	<scp>PRR11</scp> unveiled as a top candidate biomarker within the <scp>RBM3</scp> â€regulated transcriptome in pancreatic cancer. Journal of Pathology: Clinical Research, 2022, 8, 65-77.	3.0	5
209	MMP7 Modulation by Short- and Long-term Radiotherapy in Patients with Rectal Cancer. In Vivo, 2018, 32, 133-138.	1.3	5
210	OUP accepted manuscript. Clinical Chemistry, 2022, , .	3.2	5
211	Lymphocyte antigen 6 superfamily member D is a marker of urothelial and squamous differentiation: implications for risk stratification of bladder cancer. Biomarker Research, 2020, 8, 51.	6.8	4
212	Additive clinical impact of epidermal growth factor receptor and podocalyxin-like protein expression in pancreatic and periampullary adenocarcinomas. Scientific Reports, 2020, 10, 10373.	3.3	4
213	The Prognostic Impact of Intratumoral Aryl Hydrocarbon Receptor in Primary Breast Cancer Depends on the Type of Endocrine Therapy: A Population-Based Cohort Study. Frontiers in Oncology, 2021, 11, 642768.	2.8	4
214	Delineating the intra-patient heterogeneity of molecular alterations in treatment-na \tilde{A} -ve colorectal cancer with peritoneal carcinomatosis. Modern Pathology, 2022, , .	5 . 5	4
215	Clinical significance of RBM3 expression in surgically treated colorectal lung metastases and paired primary tumors. Journal of Surgical Oncology, 2021, 123, 1144-1156.	1.7	3
216	Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity. BMC Cancer, 2022, 22, 131.	2.6	3

#	Article	IF	CITATIONS
217	Interplay between Caveolin-1 and body and tumor size affects clinical outcomes in breast cancer. Translational Oncology, 2022, 22, 101464.	3.7	3
218	Translational Database Selection and Multiplexed Sequence Capture for Up Front Filtering of Reliable Breast Cancer Biomarker Candidates. PLoS ONE, 2011, 6, e20794.	2.5	2
219	Nuclear T-STAR Protein Expression Correlates with HER2 Status, Hormone Receptor Negativity and Prolonged Recurrence Free Survival in Primary Breast Cancer and Decreased Cancer Cell Growth In Vitro. PLoS ONE, 2013, 8, e70596.	2.5	2
220	Patient Characteristics Influence Activated Signal Transducer and Activator of Transcription 3 (STAT3) Levels in Primary Breast Cancer—Impact on Prognosis. Frontiers in Oncology, 2020, 10, 1278.	2.8	2
221	Clinical significance of stromal ER and PR expression in periampullary adenocarcinoma. Biomarker Research, 2019, 7, 26.	6.8	1
222	Development of a Novel Weighted Ranking Method for Immunohistochemical Quantification of a Heterogeneously Expressed Protein in Gastro-Esophageal Cancers. Cancers, 2021, 13, 1286.	3.7	1